Author Affiliations: Department of General Internal Medicine, Zablocki Veterans Affairs Medical Center, and Department of Medicine, Medical College of Wisconsin, Milwaukee (Dr Jackson); Department of General Internal Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan (Dr Kuriyama); and Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan (Dr Hayashino).
Context Botulinum toxin A is US Food and Drug Administration approved for prophylactic treatment for chronic migraines.
Objective To assess botulinum toxin A for the prophylactic treatment of headaches in adults.
Data Sources A search of MEDLINE, EMBASE, bibliographies of published systematic reviews, and the Cochrane trial registries between 1966 and March 15, 2012. Inclusion and exclusion criteria of each study were reviewed. Headaches were categorized as episodic (<15 headaches per month) or chronic (≥15 headaches per month) migraine and episodic or chronic daily or tension headaches.
Study Selection Randomized controlled trials comparing botulinum toxin A with placebo or other interventions for headaches among adults.
Data Extraction Data were abstracted and quality assessed independently by 2 reviewers. Outcomes were pooled using a random-effects model.
Data Synthesis Pooled analyses suggested that botulinum toxin A was associated with fewer headaches per month among patients with chronic daily headaches (1115 patients, −2.06 headaches per month; 95% CI, −3.56 to −0.56; 3 studies) and among patients with chronic migraine headaches (n = 1508, −2.30 headaches per month; 95% CI, −3.66 to −0.94; 5 studies). There was no significant association between use of botulinum toxin A and reduction in the number of episodic migraine (n = 1838, 0.05 headaches per month; 95% CI, −0.26 to 0.36; 9 studies) or chronic tension-type headaches (n = 675, −1.43 headaches per month; 95% CI, −3.13 to 0.27; 7 studies). In single trials, botulinum toxin A was not associated with fewer migraine headaches per month vs valproate (standardized mean difference [SMD], −0.20; 95% CI, −0.91 to 0.31), topiramate (SMD, 0.20; 95% CI, −0.36 to 0.76), or amitriptyline (SMD, 0.29; 95% CI, −0.17 to 0.76). Botulinum toxin A was associated with fewer chronic tension-type headaches per month vs methylprednisolone injections (SMD, −2.5; 95% CI, −3.5 to −1.5). Compared with placebo, botulinum toxin A was associated with a greater frequency of blepharoptosis, skin tightness, paresthesias, neck stiffness, muscle weakness, and neck pain.
Conclusion Botulinum toxin A compared with placebo was associated with a small to modest benefit for chronic daily headaches and chronic migraines but was not associated with fewer episodic migraine or chronic tension-type headaches per month.
Jackson JL, Kuriyama A, Hayashino Y. Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults: A Meta-analysis. JAMA. 2012;307(16):1736–1745. doi:10.1001/jama.2012.505
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: